Increase in women appointed to life science boards, but their talent needs to be better managed

14 October 2014

Although life science company boards are recruiting more women, a lack of managing their talent during their career is slowing the progress towards greater diversity, according to life sciences human resources specialist RSA’s biannual survey of non-executive directors.

Female board members on the rise

The company’s research shows that the number of women serving in non-executive board roles has jumped by 33% since 2012. While an increase from 12% to 16% in the past two years looks good for the life sciences industry, RSA says the rise is due to existing women board members taking on more roles within the board, not new women joining.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK